Lipids & metabolic liver disease
Longitudinal economic burden of incident complications among metabolic syndrome populations
Authors' conclusion
The economic burden from costly incident complications (i.e., cardiovascular diseases, peripheral vascular diseases, cancers), MS-related risk factors (i.e., morbid obesity), and comorbidities (i.e., depression) highlight the urgent need for early intervention to prevent MS and its progression. The comprehensive cost estimates reported in this study can facilitate the parameterization of economic analyses to identify cost-effective interventions for these patients.
Study context
- Population
- Individuals with metabolic syndrome (MS) identified from linked 2013 National Health Interview Survey and 2012–2021 National Health Insurance Research Database data
- Participants
- 837 individuals
- Outcome
- Incidence rates and healthcare cost impact of incident complications, MS-related risk factors and comorbidities
Methodological detailslinked survey and claims data, generalized estimating equation model, Sensitivity analyses on variables with high missing rates (cause of death, BMI)
- Linked survey and claims data
- Generalized estimating equation model
- Sensitivity analyses on variables with high missing rates (cause of death, BMI)
Main finding
As reported in the abstract
Incidence rates and cost impact of incident complications · follow-up 8.28 (± 1.35) years
- Incidence rate, nephropathy/retinopathy/neuropathy (events per 100 person-years)
- 6.49/2.64/2.08
- Incidence rate, CVD (events per 100 person-years)
- 2.47
- Incidence rate, peripheral vascular diseases (events per 100 person-years)
- 2.01
- Incidence rate, cancers (events per 100 person-years)
- 1.53
- Event-year cost per person, death (costliest event)
- USD 16,429
- Cost of non-MS- and MS-related cancers (most expensive complications)
- USD 9,127-11,083
- Annual cost increase, non-MS/MS-related cancers
- 273% (181-397%)/175% (105-269%) (95% CI)
- Annual cost increase, CVD
- 159% (118-207%) (95% CI)
- Annual cost increase, obesity-related medical conditions
- 140% (84-214%) (95% CI)
- Annual cost increase, nephropathy/neuropathy/retinopathy (lowest cost impact)
- 27% [17-39%]/27% [11-46%]/24% [11-37%]
Observational data: associations, not effects.
Further findings
Existing comorbidities
- Annual cost increase, from osteoarthritis to depression
- 20% to 108%
Morbid obesity (BMI ≥ 35 kg/m²)
- Annual cost increase
- 58% (30-91%) (95% CI)
Original publication
Longitudinal economic burden of incident complications among metabolic syndrome populations. Cardiovasc Diabetol. Published 10 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →